Tolmar is a specialty pharmaceutical company founded in 2007, focused on developing and delivering long-acting injectable treatments. Its core therapeutic areas are urology, oncology, and endocrinology. The company's products are available in 68 countries worldwide.
A central part of Tolmar's work involves pharmaceutical drug delivery, polymer development, and long-acting injectable formulation. One of its key products is the first six-month LHRH injectable treatment, used for conditions including central precocious puberty and advanced prostate cancer. The company maintains a vertically integrated approach to emphasize quality and control throughout the development process.
The organization describes a culture oriented toward advancing patient care and experience, with a stated motivation to discover and transform approaches within the pharmaceutical field.
